GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeoImmuneTech Inc (XKRX:950220) » Definitions » Current Accrued Expense

NeoImmuneTech (XKRX:950220) Current Accrued Expense : ₩0.00 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is NeoImmuneTech Current Accrued Expense?

NeoImmuneTech's Current Accrued Expense for the quarter that ended in Dec. 2023 was ₩0.00 Mil.


NeoImmuneTech Current Accrued Expense Historical Data

The historical data trend for NeoImmuneTech's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoImmuneTech Current Accrued Expense Chart

NeoImmuneTech Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Current Accrued Expense
- - - - -

NeoImmuneTech Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

NeoImmuneTech Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.


NeoImmuneTech Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of NeoImmuneTech's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.


NeoImmuneTech (XKRX:950220) Business Description

Traded in Other Exchanges
N/A
Address
2400 Research Boulevard, Suite 250, Rockville, MD, USA, 20850
NeoImmuneTech Inc is a clinical-stage T cell-focused biotech company dedicated to the discovery and development of novel immuno-therapeutics. Its lead asset NT-I7 is the clinical stage IL-7, which enhances the body's immune function to address key resistance mechanisms in Immuno-Oncology and deadly infectious diseases.

NeoImmuneTech (XKRX:950220) Headlines

No Headlines